Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atreleuton. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 known ✓ | P09917 | 18/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 7/20 | 1.00 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atreleuton SCHEMBL2107799 | 1.00 | ALOX5 (1.00) | ALOX5EPHX2ACACBACACA | |
| Atreleuton SCHEMBL504818 | 1.00 | ALOX5 (1.00) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL13140100 | 0.91 | ALOX5 (0.83) | ALOX5EPHX2 | |
| SCHEMBL8309861 | 0.90 | ALOX5 (0.82) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL8305234 | 0.90 | ALOX5 (0.82) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL2109641 | 0.89 | ALOX5 (0.80) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL2109638 | 0.89 | ALOX5 (0.80) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL8303838 | 0.88 | ALOX5 (0.79) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL8303836 | 0.88 | ALOX5 (0.79) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL8948277 | 0.88 | ALOX5 (0.78) | ALOX5EPHX2ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332143-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | PLUTO INC (KR) | 2025-10-30 | — | — | US | claimed |
| EP-4494639-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | Pluto Inc. (KR) | 2025-01-22 | — | — | EP | claimed |
| US-20240299347-A1 | METHODS AND COMPOSITIONS TO TREAT HUNTINGTON'S DISEASE BY TARGETING ALOX5- MEDIATED FERROPTOSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-09-12 | — | — | US | claimed |
| WO-2023177128-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | 주식회사 플루토 | 2023-09-21 | — | — | WO | claimed |
| US-7132441-B2 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. (US) | 2006-11-07 | — | — | US | claimed |
| CN-1655846-A | Combination of a PDE inhibitor and a leukotriene receptor antagonist | ALTANA PHARMA AG (DE) | 2005-08-17 | — | — | CN | claimed |
| US-20050014762-A1 | Combination | NYCOMED GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| EP-1429843-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA Pharma AG (DE) | 2004-06-23 | — | — | EP | claimed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| EP-0667855-B1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LAB (US) | 1999-03-24 | — | — | EP | claimed |
| WO-1998058645-A1 | (S)-(-)-N-[3- [5-[(4-FLUOROPHENYL)METHYL] -2-THIENYL]-1-METHYL -2-PROPYNYL]-N-HYDROXYUREA | SEPRACOR, INC. (US) | 1998-12-30 | — | — | WO | claimed |
| EP-0667855-A4 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS. | ABBOTT LAB (US) | 1996-02-21 | — | — | EP | claimed |
| EP-0667855-A1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1995-08-23 | — | — | EP | claimed |
| WO-1994011342-A1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1994-05-26 | — | — | WO | claimed |
| US-5288751-A | [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | claimed |
| US-20260146064-A1 | PH-SENSITIVE MEMBRANE DISRUPTIVE PEPTIDES AND USE THEREOF | SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) | 2026-05-28 | — | — | US | disclosed |
| US-12612631-B2 | Small RNA medicament for prevention and treatment of inflammation-related diseases and combination thereof | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2026-04-28 | — | — | US | disclosed |
| EP-0667855-A1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994011342-A1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1994-05-26 | — | — | WO | disclosed |
| US-5288751-A | [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299347-A1 | METHODS AND COMPOSITIONS TO TREAT HUNTINGTON'S DISEASE BY TARGETING ALOX5- MEDIATED FERROPTOSIS | ALOX5, ALOX15, ALOX15B | ALOX5 1/4885EPHX2 433/4885ACACB 629/4885 |
| US-12612631-B2 | Small RNA medicament for prevention and treatment of inflammation-related diseases and combination thereof | EIF2AK2, IL1A, IRF3 | ALOX5 2093/4885EPHX2 1937/4885ACACB 1377/4885 |
| US-20260146064-A1 | PH-SENSITIVE MEMBRANE DISRUPTIVE PEPTIDES AND USE THEREOF | LNPK, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, YWHAZ | ALOX5 3322/4885EPHX2 3879/4885ACACB 4777/4885 |
| US-20250332143-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | MYOF, ALOX5, MYLK2 | ALOX5 2/4885EPHX2 1953/4885ACACB 1123/4885 |
| US-20050014762-A1 | Combination | PDE4A, PDE4B, PDE3B | ALOX5 84/4885EPHX2 327/4885ACACB 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.